EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 e CIS) - Resumo da atualização 2026 Guidelines
OncologiaSobre o estudo
- Desenho
- Diretriz clínica
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European urology
- Publicado em
- 15 jul 2026
- Citações
- 14
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update
Paolo Gontero, Paramananthan Mariappan, Benjamin Pradère, Bhavan P Rai, Fredrik Liedberg, Eva Compérat, Jeremy Yuen-Chun Teoh, Marco Moschini, Francesco Soria, Bas W G van Rhijn et al.
Descritores MeSH
- Carcinoma in Situ
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Carcinoma, Transitional Cell
- BCG Vaccine
- Urology
- Humans
Veja também
Estudos relacionados
- Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC
- Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update
- Prospective comparative evaluation of clinical efficacy and safety of Intravesical gemcitabine-docetaxel versus BCG in adjuvant management of BCG-naive non-muscle invasive urothelial bladder cancer in Indian population